CA3242927A1 - TISSUE-SPECIFIC IMAGING AND THERAPEUTIC AGENTS TARGETING PROTEINS EXPRESSED ON MUSCLE CELL SURFACE - Google Patents
TISSUE-SPECIFIC IMAGING AND THERAPEUTIC AGENTS TARGETING PROTEINS EXPRESSED ON MUSCLE CELL SURFACEInfo
- Publication number
- CA3242927A1 CA3242927A1 CA3242927A CA3242927A CA3242927A1 CA 3242927 A1 CA3242927 A1 CA 3242927A1 CA 3242927 A CA3242927 A CA 3242927A CA 3242927 A CA3242927 A CA 3242927A CA 3242927 A1 CA3242927 A1 CA 3242927A1
- Authority
- CA
- Canada
- Prior art keywords
- tissue
- cell surface
- therapeutic agents
- muscle cell
- proteins expressed
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0058—Antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263297245P | 2022-01-07 | 2022-01-07 | |
| US63/297,245 | 2022-01-07 | ||
| PCT/US2023/060253 WO2023133522A2 (en) | 2022-01-07 | 2023-01-06 | Tissue-specific imaging and therapeutic agents targeting proteins expressed on muscle cell surface |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3242927A1 true CA3242927A1 (en) | 2023-07-13 |
Family
ID=87074312
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3242927A Pending CA3242927A1 (en) | 2022-01-07 | 2023-01-06 | TISSUE-SPECIFIC IMAGING AND THERAPEUTIC AGENTS TARGETING PROTEINS EXPRESSED ON MUSCLE CELL SURFACE |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250025569A1 (https=) |
| EP (1) | EP4460333A4 (https=) |
| JP (1) | JP2025504375A (https=) |
| KR (1) | KR20240130136A (https=) |
| CN (1) | CN119053346A (https=) |
| AU (1) | AU2023205141A1 (https=) |
| CA (1) | CA3242927A1 (https=) |
| IL (1) | IL314093A (https=) |
| TW (1) | TW202345894A (https=) |
| WO (1) | WO2023133522A2 (https=) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6413740B1 (en) * | 1995-12-15 | 2002-07-02 | Regeneron Pharmaceuticals, Inc. | Tyrosine kinase receptors and ligands |
| US7355018B2 (en) * | 2003-09-30 | 2008-04-08 | Regeneron Pharmaceuticals, Inc. | Modified IGF1 polypeptides with increased stability and potency |
| WO2019074489A1 (en) * | 2017-10-10 | 2019-04-18 | Flagship Biosciences, Inc. | METHODS FOR QUANTITATIVE EVALUATION OF MUSCLE FIBERS IN MUSCLE DYSTROPHY |
| IL280536B2 (en) * | 2018-08-02 | 2024-12-01 | Dyne Therapeutics Inc | Complexes targeting transferrin receptor and uses thereof |
| KR20220125801A (ko) * | 2020-01-10 | 2022-09-14 | 다인 세라퓨틱스, 인크. | 근육 표적화 복합체 및 안면견갑상완 근육 이영양증을 치료하기 위한 그의 용도 |
-
2023
- 2023-01-06 TW TW112100633A patent/TW202345894A/zh unknown
- 2023-01-06 CA CA3242927A patent/CA3242927A1/en active Pending
- 2023-01-06 WO PCT/US2023/060253 patent/WO2023133522A2/en not_active Ceased
- 2023-01-06 KR KR1020247026374A patent/KR20240130136A/ko active Pending
- 2023-01-06 CN CN202380021119.4A patent/CN119053346A/zh active Pending
- 2023-01-06 AU AU2023205141A patent/AU2023205141A1/en active Pending
- 2023-01-06 JP JP2024540881A patent/JP2025504375A/ja active Pending
- 2023-01-06 EP EP23737794.0A patent/EP4460333A4/en active Pending
- 2023-01-06 IL IL314093A patent/IL314093A/en unknown
-
2024
- 2024-07-02 US US18/762,429 patent/US20250025569A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20240130136A (ko) | 2024-08-28 |
| WO2023133522A3 (en) | 2023-09-28 |
| US20250025569A1 (en) | 2025-01-23 |
| EP4460333A4 (en) | 2026-01-14 |
| TW202345894A (zh) | 2023-12-01 |
| EP4460333A2 (en) | 2024-11-13 |
| WO2023133522A2 (en) | 2023-07-13 |
| IL314093A (en) | 2024-09-01 |
| AU2023205141A1 (en) | 2024-08-22 |
| CN119053346A (zh) | 2024-11-29 |
| JP2025504375A (ja) | 2025-02-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW200608993A (en) | Tissue-specific imaging and therapeutic agents targeting proteins expressed on lung endothelial cell surface | |
| WO2007014108A3 (en) | Method and system for evaluating quality assurance criteria in delivery of a treament plan | |
| WO2006032134A3 (en) | Radiotherapy treatment monitoring using ultrasound | |
| WO2007033216A3 (en) | Methods and compositions for the treatment and diagnosis of diseases characterized by vascular leak, hypotension, or a procoagulant state | |
| WO2008013859A3 (en) | Peptide probes for diagnostics and therapeutics | |
| WO2006127007A3 (en) | Methods of using adipose tissue-derived cells in the treatment of cardiovascular conditions | |
| EP4410367A3 (en) | Systems for shuttle mode radiation delivery | |
| WO2001091728A3 (en) | Nanoemulsion formulations | |
| WO2007120557A3 (en) | Method and apparatus of low strengh electric field network-mediated delivery | |
| WO2006014159A3 (en) | Methods of using regenerative cells in the treatment of musculoskeletal disorders | |
| WO2008070666A3 (en) | Compositions and methods to treat cancer with cpg rich dna and cupredoxins | |
| WO2023180811A3 (en) | Monitoring tissue permeability during ultrasound procedures | |
| WO2006089340A3 (en) | Polynucleotide delivery to cardiac tissue | |
| WO2007092427A3 (en) | Treatment of endotoxemia using endotoxin neutralizing agents | |
| WO2007035474A3 (en) | Transdermal delivery peptides and method of use thereof | |
| WO2020225799A3 (en) | A method of decreasing concentration of tau (τ) protein and/or phosphorylated tau (τ) protein | |
| WO2005117999A3 (en) | Imaging and therapeutic agents targeting proteins expressed on endothelial cell surface | |
| WO2000009754A3 (en) | HUMAN STEAROYL-CoA DESATURASE-RELATED COMPOSITIONS AND METHODS FOR TREATING SKIN DISORDERS | |
| WO2009138477A3 (en) | Epithelial delivery | |
| CA3242927A1 (en) | TISSUE-SPECIFIC IMAGING AND THERAPEUTIC AGENTS TARGETING PROTEINS EXPRESSED ON MUSCLE CELL SURFACE | |
| WO2006022612A3 (en) | Methods of using regenerative cells in the treatment of stroke and related diseases and disorders | |
| WO2006058231A3 (en) | Viral vectors | |
| WO2009054957A3 (en) | Methods for diagnosis and treatment of chronic fatigue syndrome | |
| WO2006042017A3 (en) | Treatment of pulmonary hypertension using an agent that inhibits a tissue factor pathway | |
| EP4450120A3 (en) | Neuromodulation techniques |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT Effective date: 20240702 |
|
| A15 | Pct application entered into the national or regional phase |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT Effective date: 20240702 |
|
| P18 | Priority claim added or amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P104 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR PRIORITY RECEIVED Effective date: 20240702 Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT Effective date: 20240702 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W00-W00-W005 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: INACTIVE: FIRST IPC ASSIGNED Effective date: 20240702 Free format text: ST27 STATUS EVENT CODE: A-1-1-W00-W00-W128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: INACTIVE: IPC ASSIGNED Effective date: 20240702 Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20240702 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W00-W00-W128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: INACTIVE: IPC ASSIGNED Effective date: 20240703 Free format text: ST27 STATUS EVENT CODE: A-1-1-W00-W00-W005 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: INACTIVE: FIRST IPC ASSIGNED Effective date: 20240703 Free format text: ST27 STATUS EVENT CODE: A-1-1-W00-W00-W270 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: INACTIVE: SEQUENCE LISTING - RECEIVED Effective date: 20240703 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-P146 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: BSL VERIFIED - NO DEFECTS Effective date: 20240722 |
|
| R11 | Change to the name of applicant or owner or transfer of ownership requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R11-R127 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER RECORDAL REQUEST OR RESPONSE Effective date: 20241104 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241104 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241223 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241223 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241223 |
|
| R14 | Transfer of ownership recorded |
Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R14-R129 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250308 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260105 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260105 |